Qiagen N.V. stock (NL0012169213): Q1 earnings meet EPS but miss revenue

Qiagen N.V. released Q1 2026 results on May 6, hitting EPS estimates at $0.54 but falling short on revenue of $492.32 million versus $496.15 million expected. The company issued full-year guidance below consensus.

Qiagen N.V. announced its first-quarter 2026 earnings on May 6, 2026, reporting earnings per share of $0.54, which matched analyst consensus estimates of $0.54, MarketBeat as of May 2026. Quarterly revenue came in at $492.32 million, missing expectations of $496.15 million. The results prompted the company to provide full-year EPS guidance of $2.43 and revenue guidance of $2.1 billion, both below consensus forecasts of $2.51 EPS and $2.2 billion in sales.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Qiagen N.V.
• Sector/industry: Life Sciences Tools & Services
• Headquarters/country: Netherlands
• Core markets: US, Europe, Asia
• Key revenue drivers: Sample technologies, bioinformatics
• Home exchange/listing venue: NYSE (QGEN)
• Trading currency: USD

Qiagen N.V.: core business model

Qiagen N.V. develops and markets sample collection, preservation, and molecular testing technologies for life sciences, applied testing, pharma, and academia. The company provides instruments, consumables, and digital solutions for nucleic acid extraction and analysis. Its portfolio includes PCR and next-generation sequencing products used in diagnostics and research worldwide. Qiagen generates recurring revenue from consumables, which account for the majority of sales.

Main revenue and product drivers for Qiagen N.V.

Key revenue streams stem from sample technologies (over 50% of sales), bioinformatics software, and assays for infectious disease testing and genomics. In Q1 2026, the company reported trailing 12-month EPS of $1.91 with a P/E ratio of 17.26, per MarketBeat as of May 2026. Growth is driven by demand in precision medicine and companion diagnostics, particularly in the US market where Qiagen holds significant share.

Industry trends and competitive position

The life sciences tools sector benefits from rising demand for genomic sequencing and personalized medicine, with US biotech funding supporting innovation. Qiagen competes with Thermo Fisher and Illumina but differentiates through automation platforms like the QIAcube. Its exposure to US pharma R&D makes it relevant for American investors tracking healthcare innovation.

Why Qiagen N.V. matters for US investors

Listed on NYSE as QGEN, Qiagen derives substantial revenue from US customers in diagnostics and biopharma. The company's technologies support FDA-approved tests, aligning with US regulatory standards and market growth in molecular diagnostics, a sector projected to expand amid aging demographics and chronic disease prevalence.

Conclusion

Qiagen N.V.'s Q1 2026 earnings showed resilience in EPS amid a revenue miss, with guidance signaling cautious full-year outlook. The company's strong position in molecular diagnostics continues to drive relevance, especially for US investors via its NYSE listing and pharma exposure. Market reactions and future quarters will shape the trajectory amid sector tailwinds.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.